A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

A Phase 1, Double-blind, Two-arm, Mechanism of Action Study to Investigate the Effect of Orforglipron on Body Composition in Adult Participants With Obesity or Overweight, Without Diabetes

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

Inclusion Criteria:

• Have a Body Mass Index (BMI)

  • ≥30.0 kilograms per square meter (kg/m2), or
  • ≥27.0 kg/m2 with comorbidities

Exclusion Criteria:

• Have type 1 diabetes, type 2 diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
• Have an unstable body weight within 90 days prior to screening
• Have acute or chronic hepatitis
• Are taking other medications or alternative remedies to manage weight loss